The influence of previous hormone therapy on PSA response in prostate cancer patients (PTS) failing first-line androgen ablation

被引：0
|
作者：
Rassweiler, J [1 ]
机构：
[1] STADTKRANKENHAUS HEILBRONN,HEILBRONN,GERMANY
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [41] Assessing the Supplementary Role of PSMA PET Parameters in Metastatic Hormone-Sensitive Prostate Cancer Patients Initiating First-Line Therapy
    Zanca, R.
    Aliprandi, M.
    Cecchi, L.
    Bertocchi, A.
    Borea, F.
    Cordua, N.
    Perrino, M.
    De Vincenzo, F.
    Rodari, M.
    Jandric, J.
    Muraglia, L.
    Zucali, P.
    Evangelista, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S526 - S526
  • [42] Potential modulating effects of micronutrients on prostate specific antigen (PSA) response to androgen deprivation therapy in prostate cancer
    Resh, J
    Kannan, S
    Wei, JT
    Dunn, R
    FASEB JOURNAL, 2002, 16 (04): : A371 - A371
  • [43] Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer
    Roviello, Giandomenico
    Petrioli, Roberto
    Francini, Edoardo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (03): : 326 - 328
  • [44] Evaluation of PSA Patterns in Patients With Localized Prostate Cancer Treated With Radiation Therapy and Androgen Deprivation Therapy
    Yang, T.
    Pei, X.
    Zhang, Z.
    Kollmeier, M.
    Spratt, D.
    Zumsteg, Z.
    Polkinghorn, W.
    McBride, S.
    Zelefsky, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S428 - S428
  • [45] Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
    Zhao, Yan
    Liang, Jie
    Wang, Qian
    Cao, Jing-Yi
    Yin, Zhi-Xiang
    Peng, Yu-Hao
    Gai, Nian-Xin
    Pei, Chang -Song
    JOURNAL OF MENS HEALTH, 2023, 19 (07) : 39 - 44
  • [46] Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy
    Inci, Bediz Kurt
    Gurler, Fatih
    Sutcuoglu, Osman
    Bastug, Vural
    Yazici, Ozan
    Uner, Aytug
    Ozet, Ahmet
    Ozdemir, Nuriye
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 : S845 - S850
  • [47] Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed
    Ornstein, DK
    Smith, DS
    Andriole, GL
    UROLOGY, 1998, 52 (06) : 1094 - 1097
  • [48] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [49] The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naive Prostate Cancer Patients
    Sasaki, Takeshi
    Sugimura, Yoshiki
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [50] Prognostic factors of prostate cancer treated by first-line endocrine therapy.
    Rigaud, J
    Le Normand, L
    Karam, G
    Glemain, P
    Buzelin, JM
    Bouchot, O
    PROGRES EN UROLOGIE, 2002, 12 (02): : 232 - 239
12345